The presence of amyloid plaques in the brain is one of prominent histological features of Alzheimer's disease. However, imaging of amyloid plaques in vivo in humans is not yet feasible. Recent technical advances in high resolution magnetic resonance imaging (MRI) methods in mice have enabled not only the detection of amyloid plaques in vivo but also allowed to monitor the development of these plaques with age in the same animals. Further technical improvements to visualize small plaques at early stages at ultrahigh magnetic fields are underway. This review summarizes some of the current developments in visualizing AD plaques in vivo in mice and highlights their future impact on drug discovery. Furthermore potential application and challenges of translation of these methods for visualizing plaques in human are discussed.
INTRODUCTION
Alzheimer's disease (AD) is the most frequent neurodegenerative disorder with no effective treatment or definitive antemortem diagnostic test. AD increases in incidence exponentially with age and is therefore emerging as a leading health problem as populations are constantly aging. The disease is characterized by a disruption of the neuronal function, progressive memory loss and gradual cognitive, functional and behavioral deterioration [1, 2] . The presence of senile plaques and neurofibrillary tangles in the brain are the most prominent pathological features of AD and postmortem observation of both of these neuro-pathologies in histological sections is still necessary for final confirmation of AD. The ability to visualize either of these pathologies with an in vivo imaging technique coupled with clinical diagnosis would add a large degree of confidence to the diagnosis of AD. While neurofibrillary tangles are located intracellularly, senile plaques are distributed extracellularly over wide areas of the brain and are considered a promising target for a potential biomarker [3, 4] .
The core of senile plaques consists mainly of aggregated amyloidogenic peptide A , a highly hydrophobic peptide that spontaneously aggregates in vitro [5] . The amyloid (A ) protein is a 39-to 43-amino acid protein derived through proteolytic processing of a larger membrane bound glycoprotein, the amyloid protein precursor (APP) [2] . Recent studies have shown that in AD brain, A protein with 42 amino acid residues (A 1-42) is deposited first and is the predominant form in senile plaques. In contrast, A protein with 40 amino acid residues (A 1-40) is deposited later in the disease and is prominent in vascular amyloid deposits [6] . During aggregation single monomeric A peptides bind together to form oligomeric strings which assemble into fibrillar sheets and multiple fibrils bind to form the backbone of the amyloid plaque, trapping other macromolecules along the way [7, 8] . The amyloid in senile plaques forms a spherical core that ranges from ~2 to ~200 μm. Although according to recent consensus the occurrence of A plaques does not correlate well with neuronal loss and the presence or severity of dementia, the disordered metabolism of A is central to the pathological cascade that ultimately leads to clinical AD [9, 10] . Consequently, amyloid reduction in humans is now a major therapeutic objective. The map of plaque deposition established in postmortem tissue indicates that amyloid plaques begin in the neocortex, across the temporal, parietal and frontal lobes, while the hippocampal formation has been implicated as a secondary site of plaque deposition [11] . However, to establish a genuine map of plaque deposition as the disease progresses in living subjects is difficult, due to a lack of in vivo imaging methods for visualizing the development of amyloid plaques in humans.
Due to the importance of visualizing A plaques in vivo for evaluation and assessment of possible therapeutic interventions of AD, much work has focused on developing an imaging technique for resolving plaques. A major recent breakthrough in the field of imaging in AD has been the development of amyloid imaging tracers for positron emission tomography (PET) [12] [13] [14] . Although scintigraphic markers such as the "Pittsburgh-B" compound have been developed that can visualize the plaque burden with PET in living Alzheimer's patients [15] , individual plaques are beyond the resolution of PET. Contrary to PET, MRI does not require use of ionizing radiation and permits obtaining a much higher spatial resolution. However, to date its potential for in vivo amyloid imaging has only been explored in transgenic mice. Considerable progress has been made in MR imaging of A plaque using genetically engineered mice with mutations that lead to accelerated A production and plaque deposition ( Table 1) . In this review we focus on advances made in visualization of A plaques with magnetic resonance imaging using several different lines of transgenic mouse models of AD with emphasis on the recent longitudinal studies that enabled the visualization of plaque development in the same animals with age and their future impact on drug discovery. In addition, potential applications and challenges in the translation of these methods for visualizing plaques in humans are discussed. 
EX VIVO IMAGING OF AMYLOID PLAQUES USING MRI
One key theoretical advantage of MRI is its superior spatial resolution. Furthermore, MRI is safe, which is particularly important for repeated scanning to allow the longitudinal course of plaque load to be mapped. Over the last several years, multiple research groups have developed techniques to image amyloid plaque load. Several studies involving imaging of amyloid plaques ex vivo in human and ex vivo and in vivo in different transgenic mouse models of AD are discussed in earlier reviews [8, 10, 16, 17] . An updated overview of these studies is summarized chronologically in Table  1 . As is clear from this overview the first successful attempt to visualize plaques in fixed human tissue was achieved by Benveniste et al. [18] using T 2 *-weighted MRI at 7T with a spatial resolution in the range of 40 40 40 μm (~6 10 -5 mm 3 ). Plaques emerged as black, spherical elements on T 2 * MRMs and this was attributed to the known presence of metals, particularly iron in plaques. This finding was not replicated in another study which reported the dark spots to be vascular structures [19] . Dhenain et al. [19] observed hypointensities in ex vivo human tissue at 11.7T but concluded that most of the hypointensities observed were blood vessels and did not represent plaques. Subsequently several types of transgenic mouse models of AD have also been used to visualize plaques in fixed mouse brain at various field strengths such as 4.7T, 7T and 9.4T [21] [22] [23] [24] ( Table 1) . The measuring time in these studies varied from 65 min to up to 11h. Two types of sequence were mainly used: spin echo (SE) and gradient echo sequences. The highest resolution that was achieved in these animal experiments was 46 72 72 μm using the SE sequence at 9.4T in 14 h [20] . The measuring time has been further reduced by optimized SE sequences to obtain plaque visualization within 1h 40 minutes with a reasonable resolution of 60 60 120 μm [21] . The gradient echo sequences have been utilized for ex vivo imaging of plaques in the mouse brain that were stained with unspecific [22] or target specific [23] gadolinium based contrast agents.
Faber et al. [25] have used ultra high magnetic field (17.6T) to visualize amyloid plaques in the thalamus in a transgenic mouse model of AD. They explored the feasibility of obtaining bright contrast from plaques in fixed mouse brains using the COSY revamped with asymmetric z-GE detection (CRAZED) sequence [25] (Fig. 1B) . When CRAZED images were acquired with mismatched gradients, elevated signal was obtained at the location of the plaques within 6.4 min, while background signal was suppressed almost to the noise level. This bright contrast obtained from the plaques was due to the local dipole field originating from iron in the plaques which locally refocuses magnetization in the mismatched CRAZED image. Thus this technique can only visualize plaques which contain a sufficient amount of iron. Similar bright-contrast visualization of plaques was realized with a mismatched gradient echo sequence [25] . With this technique bright-contrast images at the location of the plaques were obtained within only 2.6 min with an inplane resolution of 59 m [25] . Thus sensitivity of gradient echo imaging to dipole fields afforded faster detection of iron-loaded plaques at ultrahigh field than has been achieved at lower fields. However, bright contrast imaging techniques are prone to producing increased signal based on other sources of local dipole fields such as blood clots. For reliable quantification of plaque load with this technique would require the information of the iron content per plaque, which usually is not available. Thus, for the detection of plaques without additional labeling, bright-contrast techniques are not likely to provide advantages compared to conventional methods [25] . However, in combination with contrast agents that target amyloid plaques, bright-contrast techniques may allow visualization of even small size plaques which can facilitate early diagnosis of AD. Since the efficiency of bright-contrast imaging relies on the product of local magnetization and magnetic field strength, the technique can also be applicable at clinical field strengths, provided individual plaques can be labeled with a sufficient amount of iron for contrast enhancement [25] . Combined with such contrast agents, bright-contrast methods may potentially become applicable for diagnosing AD in patients by visualizing plaques in the brain non-invasively. In the same study, Faber et al. [25] have also used SE sequence at 17.6T which detected hypointensities near the plaques in the thalamus region in a scan time of only 6.4 min [25] .
Summarizing the results from various ex-vivo studies, it can be concluded that iron containing plaques in the thalamus regions can be visualized in a scan time as short as 1min with the gradient echo sequence and in 6.4 min with SE sequences at 17.6T [25] . The cortical plaques with endogenous contrast can be visualized best with optimized SE sequence in a minimum time of 1h 40 min at 9.4T with a resolution of 60 60 120 m [21] .
IN VIVO IMAGING OF AMYLOID PLAQUES
Two types of in vivo amyloid imaging have been adapted in the last few years. One is the ligand-based approach [26, 27] which uses exogenous MR contrast ligands that specifically binds to plaques and the other is non-ligand-based approach in which MRI contrast is generated by the endogenous chemical make-up of amyloid plaques [21, 25, [28] [29] [30] [31] . While both approaches have several advantages and limitations, the endogenous contrast based approach has been successfully used for longitudinal studies in monitoring the development of A plaques with age in the same animals [31] .
Ligand-Based Approach
The ligand-based approaches for successful plaque visualization in vivo in transgenic mice have been used in two studies so far. The first reported study was by Wadghiri et al. in 2003 [26] . Relying on the fact that A peptide itself avidly binds amyloid plaques, they developed an effective MRI sensitive plaque ligand by attaching either gadolinium or iron nanoparticles to A . The plaques were visualized at 7T, using T 2 weighted SE and T 2 * weighted gradient echo sequences, and spatial resolutions of 59 59 500 μm and 59 59 250 μm were obtained, in scan times of 1-2 hrs. Although the results of this study are convincing, the ligand does not spontaneously pass through the blood-brain barrier, necessitating co-administration of mannitol to increase permeability of the blood-brain barrier so that the ligand can gain access to the brain. Due to the neurotoxicity of A and the requirement for mannitol injection, these methods may have limited utility in a clinical setting. Subsequently, Higuchi et al. [27] reported another novel ligand-based approach for visualization of A plaques in living transgenic AD mice. They used Congo Red-based amyloidophilic compounds that are labeled with MRI-sensitive 19 fluorine ( 19 F). Because 19 F is naturally present in extremely low concentrations in the body, 19 F-based MRI has virtually no background noise. The authors showed that when this 19 F-containing ligand is injected intravenously into living transgenic mice, it successfully crosses the blood-brain barrier and binds amyloid plaques and this binding can be successfully detected with 19 F-MRI. They proposed that this approach can be used for longitudinal studies in mouse models of AD [27] ; although no follow-up longitudinal study has been published so far using this approach. It is interesting to note that 19 F-MRI containing ligands are not specific to only amyloid plaques since they bind amyloid plaques, neurofibrillary tangles and perhaps even Lewy bodies or other -sheet inclusions. However, sensitivity of ligands to both amyloid plaques and neurofibrillary tangle may be diagnostically relevant for AD, since both phenomena are relevant histological hallmarks for the disease.
Non-Ligand-Based Approach
Using a non-ligand-based approach, a number of groups have pursued imaging of amyloid plaques with MRI exploiting the intrinsic contrast of the plaques [21, 25, [28] [29] [30] [31] . Various T 2 -, T 2 *-and T 1rho -weighted sequences have been successfully implemented to image amyloid plaques without any contrast agents using various transgenic mouse models of AD.
Jack et al. presented two studies in which A plaques had been successfully visualized in live mouse brain, without the need for an exogenous contrast agent [21, 28] . These studies were done at 9.4T with spatial resolutions of 60 60 120 μm using an optimized T 2 weighted SE sequence. The imaging time in these studies was still 1h, 40 min and cardiorespiratory triggering was necessary to prevent motion artifacts without which plaques could not be visualized. Vanhoutte et al. [29] used basic T 2 *-weighted MRI to visualize iron containing plaques in vivo in the thalamus region of the mouse brain with a gradient echo sequence. They achieved plaque visualization with a spatial resolution of 78 156 234 μm and an imaging time of 68 minutes. The plaques in the cortex and hippocampus regions which were iron-negative could not be visualized with T 2 *-weighted MRI in this study.
Borthakur [30] demonstrated the visualization of plaques by exploiting an alternative contrast mechanism called T 1rho . T 1rho is the spin lattice relaxation time constant in the rotating frame, which determines the decay of the transverse mag- Fig. (1) . Pulse sequences used for rapid imaging of amyloid plaques by Faber et al. [25] (A) Gradient echo (GE) sequence with a mismatched slice refocusing gradient (only the slice gradient is shown). In the presence of a local dipole field Bdip (gray box), the slice refocusing gradient does not match the slice gradient (hatched areas). An additional gradient Gmis, which compensates for Bdip, is required to obtain the full GE; (B) CRAZED sequence to produce bright-contrast images near the plaques as well as from clotted bloods and air bubbles in 2.6 min. The sequence composed of two RF pulses (black bars) with flip angles and phase as indicated, and a pair of gradients selecting double quantum coherences. G and T denote the strength and duration, respectively, of the gradient pulses. After the interval t 2 =2t 1 , a coherence transfer echo forms that is read out with a symmetric SE. In the presence of a local dipole field B dip , the coherence selection gradients can be locally compensated for during t 1 and t 2 , and single-quantum coherences are directly refocused. Reproduced with permission from reference [25] © John Wiley and Sons, Inc.
netization in the presence of a 'spin-lock' radiofrequency (RF) field. T 1rho -weighted MR images are less prone to diffusion or susceptibility-induced signal loss and have a larger dynamic range [30] . Using a gradient echo based T 1rho pulse sequence at 4.7T, they were able to visualize plaques in vivo. However, the imaging time was about 3 hr to achieve a spatial resolution of 78 78 130 μm. Future studies at higher magnetic field ( 9.4T) can be useful to exploit the benefit of T 1rho -weighted MRI for plaque visualization in a shorter time.
Our group has exploited a fast spin echo (FSE) sequence to visualize A plaques using MRI [31] . In FSE imaging sequence multiple spin echoes are generated by employing multiple 180° refocusing pulses [32] . Each refocused echo is acquired after having experienced a different phase-encoding value. This reduces the total imaging time as compared to a normal SE sequence. Because refocusing of the a transverse magnetization is inherent in the sequence, it is less vulnerable to susceptibility-induced dephasing than gradient echo sequences, but it is substantially faster to apply than a SE sequence with a single-phase encoding value per repetition time. Following optimization of a T 2 -weighted FSE sequence for a 9.4T scanner, we were able to visualize individual plaques in the hippocampal and cortical regions of the brain of Tg2576 mice in a scan time as short as 25 minutes without any cardiorespiratory triggering or trigger desensitizing modification. Co-registration of plaques between in vivo MRI and corresponding A -antibody stained sections illustrates that many circular hypointense regions seen in MRI correspond to A plaques [31] .
The basis for intrinsic MRI contrast between individual plaques and normal background tissue is still not fully understood. It is presumed that the hydrophobic nature of amyloid deposits, and/or age related accumulation of iron within the plaques, can have an effect on the T 2 and T 2 * relaxation rates in and adjacent to plaques [18, 33] . Very recently, El Tannir El Tayara et al. [33] have shown that T 2 relaxation can be affected by plaque deposition even in the absence of histochemically detectable iron. House et al. [34] found no correlation between AD plaque density and iron concentration. In our recent study we examined the distribution of iron in the histological sections of the Tg2576 mouse brain [31] . Iron was found to be associated with many dense-cored senile plaques, although not all A plaques seen by immunohistology or μMRI contained iron. This suggested that iron may be contributing partly to the source of the intrinsic MR contrast from A plaques, although signal hypointensities arising from the reduced water content in A plaques compared to the surrounding tissue and from other unknown factors can not be ruled out. Amyloid plaques in AD brains can be circumscript plaques with a dense core or more diffuse plaques. Dense-core plaques are fibrillar deposits of A , showing all the classical properties of amyloid includingsheet secondary structure, while diffuse plaques are amorphous deposits of A that lack a core [35] . It is still an open question if iron is associated with dense cored plaques, diffused core plaques, or both. In addition, it is not yet clear if non-ligand based MRI approach for visualization of amyloid plaques is more specifically detecting dense core plaques and/or diffuse plaques. This aspect warrants further research efforts. This would however, require better resolution and specificity of the non-ligand based MRI approach to distinguish between dense-core and diffuse plaques.
Very recently Faber et al. published the first ultra-high field (17.6T) study of in vivo plaque visualization in transgenic AD mice [25] . Due to the increased field strength, and the corresponding increase in signal to noise, it was possible to visualize plaques in vivo in the thalamus regions with an isotropic resolution of 94 94 94μm in 34 minutes. Furthermore, the high magnetic field strength permitted in vivo detection of plaques with low-resolution of 94 234 234 μm in a scan time of only 82 s using a gradient echo sequence (Fig.  1A) . At the high magnetic field strength used, the dipole field of iron in the plaques caused strong signal dephasing in a region larger than the actual size of a plaque. Such a short scan time provides new opportunities for MR in Alzheimer research. For example, such fast amyloid detection protocols could be used for high throughput screening of a large number of transgenic mice treated with new drugs. However, in vivo visualization of plaques in the cortex and hippocampus has not yet been successful with this fast amyloid detection gradient echo protocol.
LONGITUDINAL STUDIES FOR MONITORING THE DEVELOPMENT OF PLAQUES WITH AGE
To study the pathogenesis of AD and its development over time, and for the development of adequate therapeutic agents or preventive strategies, it is important to establish non-invasive in vivo imaging methods for quantitative monitoring of plaque development over time in the same animals. Different strains of transgenic AD mice, developing plaques at different rates are available [36] . Longitudinal studies using these available transgenic mouse models can also help to validate the reliability of MRI to detect AD pathology.
Although a number of groups have reported the visualization of plaques by MRI in mice at one time point or at different time points using mice belonging to different age groups [28] , our group was the first to examine the utility of μMRI for detecting the development of A plaques in longitudinal studies in same transgenic mice with age [31] . The same Tg2576 mice were imaged at the age of 12, 14, 16 and 18 months at 9.4T using an optimized FSE sequence. A marked age-related increase in amyloid deposition in the hippocampal and cortical regions of the brain was clearly observed. The plaques increase rapidly in number, size, and the degree of compactness. Only a few circular hypointense regions corresponding to A plaques were observed in 12-month-old Tg2576 mice, while the density of A deposits, seen as dark circular hypointense regions in the cortical and hippocampal region, considerably increased at 18 months ( Fig. 2A) . Some of the A plaques observed in the brain at the age of 12 months were detected consistently at all ages, while the size of these plaques showed an increasing trend with age. The clarity of plaque detection also enabled us to quantitatively estimate the change in the plaque load and numerical density of the A plaque with age (Fig. 2C) . This quantitative estimation of A plaque load with age from μMRI images was well in line with quantification made from immunohistochemical sections [37] , confirming the reliability of μMRI techniques for longitudinal plaque detection. An increase in the plaque load with age was nicely correlated with a decrease of the mean transverse relaxation time T 2 (Fig. 2D) . In an earlier study, Jack et al. [28] provided quantitative counts of individual plaques on MRI with age using AD transgenic mice (APP/PS1) using a T 2 -weighted SE sequence, however, in these studies measurements were performed on different mice belonging to different age groups. The source of contrast between plaques and normalappearing adjacent brain tissue was inferred to be related to iron within plaques that accelerates T 2 relaxation due to the magnetic susceptibility effect induced by the iron. In a recent longitudinal study, Falangola et al. [38] have followed the change in T 2 relaxation time with age in three different mouse models of AD. Using APP, PS1 and PS1/APP mice, they showed age-associated decrease in T 2 values in all three transgenic genotypes. On the basis of the pattern of decrease in T 2 , they found that T 2 changes can precede amyloid deposition or even occur in AD models that do not depositamyloid (i.e. PS mice), but T 2 changes are intensified in the presence of amyloid deposition [38] . They concluded that reduction in T 2 seen in AD brain is likely to be related to a combination of factors, including the biological effects of the mutation, raised concentration of soluble A , disrupted iron homeostasis and iron-containing amyloid plaques. In summary, longitudinal MR studies in transgenic AD mice demonstrated that μMRI can be used to study plaque biology over very long periods and in assessing the efficacy of amyloid reduction therapies currently under development by many major pharmaceutical companies throughout the world. Furthermore, using this approach interesting biological issues could be non-invasively addressed; for example, does a particular therapeutic approach arrest plaque growth, shrink plaques, or prevent development of new plaques? Does a therapeutic have a uniform effect on all plaques, or are there significant plaque to plaque variations? 
CHALLENGES FOR THE TRANSLATION TO HU-MANS
A plaques in mice and humans are quite similar in size (20 up to 200 μm). The exciting question is obvious: Can amyloid plaques be detected in vivo in man using MRI sequences that can be realistically applied in a clinical setting? In principle, the ex vivo MRI studies in postmortem human tissue and in vivo studies in mice have set the stage for further technical innovation to extend amyloid imaging to living human subjects. However, many practical hurdles need to be overcome before this can be achieved. The low sensitivity despite long imaging time and the need to use very high field MRI systems for plaque visualization in mice suggests that the hardware and software of MRI technology needs to be further improved in terms of sensitivity and specificity to obtain sufficient contrast-to-noise ratios in humans at a slightly lower spatial resolution, and in a much shorter imaging time. The optimization of MRI protocols will be difficult because of the uncertainty of the presence of amyloid plaques in suspected Alzheimer patients. Movement artifacts are likely to be a significant problem, as it is difficult for patients with advanced Alzheimer disease to keep still even with scan duration of several minutes. However, this will not be a problem for early detection of plaques in patients that do not yet have disease symptoms. Furthermore, the specificity of the technique needs to be established to reliably differentiate A plaques from other structures with a similar appearance on MRI, such as blood vessels and small hemorrhages. Specificity may be further increased by the development of safe MR contrast agents that cross the brain-brain barrier and specifically bind to the A plaques and selectively enhance these plaques on MRI. The doses of these ligands must be low, in picomolar range rather than the micromolar range as currently used for MRI.
With the growing awareness of the feasibility of human imaging at ultrahigh fields, whole body high field MRI systems (7T) are now available. In addition, advancements in RF coil technology have improved the sensitivity and resolution of MRI. With sequence modifications such as 'radical flip angle variation', high-resolution T 2 weighted imaging at 7T is possible with large volume coverage, without an increase of the scan time imposed by the high RF-power requirement [39] . The rapid growth in interest in molecular imaging is leading to new knowledge in designing safe and sensitive MR contrast agents. Clearly, noninvasive in vivo evaluation of amyloid burden in Alzheimer's disease patients would be instrumental for the early diagnosis of AD as well as the development and monitoring of new treatment strategies.
